Osteopontin expression in plasma of melanoma patients and in melanocytic tumours

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 9, 2012, Pages 1084-1091

  Maier, T ^a   Laubender, R P ^b   Sturm, R A ^c   Klingenstein, A ^b   Korting, H C ^a   Ruzicka, T ^a   Berking, C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LACTATE DEHYDROGENASE; OSTEOPONTIN; PROTEIN S 100; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CUTANEOUS MELANOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RELIABILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TISSUE SECTION;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; OSTEOPONTIN; S100 PROTEINS; SKIN NEOPLASMS;

EID: 84865076763     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04210.x     Document Type: Article

References (41)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
2. Hauschild A, Engel G, Brenner W, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999; 56: 338-344.
3. Jury CS, McAllister EJ, MacKie RM,. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000; 143: 269-274.
4. Alber B, Hein R, Garbe C, Caroli U, Luppa PB,. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma. Clin Chem Lab Med 2005; 43: 557-563.
5. Zhou Y, Dai DL, Martinka M, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005; 124: 1044-1052.
6. Zohar R, Cheifetz S, McCulloch CA, Sodek J,. Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration. Eur J Oral Sci 1998; 106 (Suppl. 1): 401-407.
7. Shinohara ML, Lu L, Bu J, et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 2006; 7: 498-506.
8. Buback F, Renkl AC, Schulz G, Weiss JM,. Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. Exp Dermatol 2009; 18: 750-759.
9. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94: 513-521.
10. Ohyama Y, Nemoto H, Rittling S, et al. Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures. J Bone Miner Res 2004; 19: 1706-1711.
11. Philip S, Bulbule A, Kundu GC,. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001; 276: 44926-44935.
12. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW,. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 4060-4066.
13. Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R, Schaller UC,. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica 2009; 223: 239-243.
14. Reiniger IW, Wolf A, Welge-Lussen U, Mueller AJ, Kampik A, Schaller UC,. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study. Am J Ophthalmol 2007; 143: 705-707.
15. Kadkol SS, Lin AY, Barak V, et al. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 2006; 47: 802-806.
16. Pepe MS, Cai T, Longton G,. Combining predictors for classification using the area under the receiver operating characteristic curve. Biometrics 2006; 62: 221-229.
17. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
18. R Development Core Team. A language and environment for statistical computing. R Foundation for Statistica, Vienna, Austria, 2009. ISBN 3-900051-07-0.
19. StataCorp. Stata Statistical Software: Release 10. StataCorp LP, College Station, TX, 2007.
20. Bakos RM, Maier T, Besch R, et al. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma. Exp Dermatol 2010; 19: e89-e94.
21. Garbe C, Hauschild A, Volkenandt M, et al. [Brief guidelines: malignant melanoma of the skin]. J Dtsch Dermatol Ges 2006; 4: 344-349.
22. Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A,. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie 2008; 31: 380-384.
23. Krahn G, Kaskel P, Sander S, et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 2001; 21: 1311-1316.
24. Schmitz C, Brenner W, Henze E, Christophers E, Hauschild A,. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res 2000; 20: 5059-5063.
25. Egberts F, Hitschler WN, Weichenthal M, Hauschild A,. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res 2009; 19: 31-35.
26. Beyeler M, Waldispuhl S, Strobel K, Joller-Jemelka HI, Burg G, Dummer R,. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology 2006; 213: 187-191.
27. Denhardt D,. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005; 124: xvi-xviii.
28. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605-611.
29. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003; 9: 59-67.
30. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-1679.
31. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF,. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002; 95: 506-512.
32. Tronnier M, Missler U, Grotrian K, Kock N,. Does ultraviolet radiation exposure influence S100 beta protein plasma levels? Br J Dermatol 1998; 138: 1098-1100.
33. Mussack T, Kirchhoff C, Buhmann S, et al. Significance of Elecsys S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients. Clin Chem Lab Med 2006; 44: 1140-1145.
34. Fassbender K, Schmidt R, Schreiner A, et al. Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci 1997; 148: 101-105.
35. Wong CK, Lit LC, Tam LS, Li EK, Lam CW,. Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 602-606.
36. Rangel J, Nosrati M, Torabian S, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer 2008; 112: 144-150.
37. Geissinger E, Weisser C, Fischer P, Schartl M, Wellbrock C,. Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res 2002; 62: 4820-4828.
38. Sturm RA,. Osteopontin in melanocytic lesions - a first step towards invasion? J Invest Dermatol 2005; 124: xiv-xv.
39. Inoue M, Shinohara ML,. Intracellular osteopontin (iOPN) and immunity. Immunol Res 2000; 49: 160-172.
40. Shinohara ML, Kim HJ, Kim JH, Garcia VA, Cantor H,. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc Natl Acad Sci USA 2008; 105: 7235-7239.
41. Sturm RA, Satyamoorthy K, Meier F, et al. Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Res 2002; 62: 226-232.